

Att. Docket No. REG.471-PCT-US
USSN 09/204,555
Amendment in Response to October 31, 2001
Office Action and Petition for Three Month
Extension of Time

In the claims:

Please replace Claims 1 as follows:

1. (Amended) Use of a soluble form of a receptor for a growth factor for the delivery of said growth factor comprising the step of coadministering said growth factor with said soluble form of the growth factor receptor such that said growth factor and said soluble form of the growth factor receptor are delivered intracerebrally, extracerebrally, intraparenchymally, inracerebraventricularly or intrathecally.

Please replace Claim 6 as follows:

6. (Amended) Use according to claim 5 wherein said growth factor is BDNF and the soluble receptor is a TrkB-IgG receptorbody.

Please replace Claim 12 as follows:

12. (Amended) A pharmaceutical composition according to claim 11 wherein said growth factor is BDNF and the soluble receptor is a TrkB-IgG receptorbody.

Please replace Claim 18, as follows:

18. (Amended) A method according to claim 17 wherein said growth factor is BDNF and the soluble receptor is a TrkB-IgG receptorbody.

Remarks

Claims 1 - 17 remain active in this application.